FibroGen Inc (NASDAQ: FGEN) on Friday, plunged -9.52% from the previous trading day, before settling in for the closing price of $0.37. Within the past 52 weeks, FGEN’s price has moved between $0.18 and $2.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.51% over the past five years. The company achieved an average annual earnings per share of 69.86%. With a float of $93.78 million, this company’s outstanding shares have now reached $98.77 million.
Let’s look at the performance matrix of the company that is accounted for 486 employees. In terms of profitability, gross margin is 79.8%, operating margin of -62.79%, and the pretax margin is -69.6%.
FibroGen Inc (FGEN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of FibroGen Inc is 7.00%, while institutional ownership is 45.77%. The most recent insider transaction that took place on Jun 12 ’24, was worth 25,884. In this transaction Chief Medical Officer of this company bought 22,123 shares at a rate of $1.17, taking the stock ownership to the 82,123 shares. Before that another transaction happened on Mar 07 ’24, when Company’s CEO bought 50,000 for $1.91, making the entire transaction worth $95,470. This insider now owns 470,178 shares in total.
FibroGen Inc (FGEN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 69.86% per share during the next fiscal year.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
FibroGen Inc (FGEN) is currently performing well based on its current performance indicators. A quick ratio of 1.16 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ: FGEN) saw its 5-day average volume 2.62 million, a positive change from its year-to-date volume of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 67.73%. Additionally, its Average True Range was 0.05.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 11.46%, which indicates a significant decrease from 63.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.27% in the past 14 days, which was lower than the 144.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3645, while its 200-day Moving Average is $1.0524. Nevertheless, the first resistance level for the watch stands at $0.3702 in the near term. At $0.4057, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4264. If the price goes on to break the first support level at $0.3140, it is likely to go to the next support level at $0.2933. The third support level lies at $0.2578 if the price breaches the second support level.
FibroGen Inc (NASDAQ: FGEN) Key Stats
Market capitalization of the company is 30.52 million based on 100,770K outstanding shares. Right now, sales total 147,750 K and income totals -284,230 K. The company made 50,640 K in profit during its latest quarter, and -15,540 K in sales during its previous quarter.
